Literature DB >> 34219357

Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients.

Bérangère S Joly1,2, Michael Darmon3, Charlotte Dekimpe4, Thibault Dupont3, Guillaume Dumas3, Elise Yvin3, Nicolas Beranger1,2, Karen Vanhoorelbeke4, Elie Azoulay3, Agnès Veyradier1,2.   

Abstract

BACKGROUND: Critically ill patients with coronavirus disease 2019 (COVID-19) are prone to developing macrothrombosis and microthrombosis. COVID-19 has been reported to be rarely associated with thrombotic microangiopathies. A disintegrin and metalloprotease with thrombospondin type I repeats, member 13 (ADAMTS13) severe deficiency, the hallmark of thrombotic thrombocytopenic purpura (TTP), induces the formation of platelet, unusually large von Willebrand factor (VWF) multimer microthrombi. In immune-mediated TTP, ADAMTS13 adopts specifically an open conformation. The VWF/ADAMTS13 couple may contribute to the microthrombi formation in pulmonary alveolar capillaries in COVID-19.
OBJECTIVE: To investigate clinical features, hemostatic laboratory parameters, VWF/ADAMTS13 axis, and ADAMTS13 conformation in critically ill COVID-19 patients at admission.
METHODS: Fifty three critically ill COVID-19 patients were enrolled between March 18 and May 9 2020 in a monocentric hospital.
RESULTS: The median age was 59 years and the male-to-female ratio was 2.8/1. We reported seven pulmonary embolisms and 15 deaths. Biological investigations showed increased fibrinogen and factor V levels, and strongly increased D-dimers correlated with mortality. No patient presented severe thrombocytopenia nor microangiopathic hemolytic anemia. An imbalance between high VWF antigen levels and normal or slightly decreased ADAMTS13 activity levels (strongly elevated VWF/ADAMTS13 ratio) was correlated with mortality. Three patients had a partial quantitative deficiency in ADAMTS13. We also reported a closed conformation of ADAMTS13 in all patients, reinforcing the specificity of an open conformation of ADAMTS13 as a hallmark of TTP.
CONCLUSION: We suggest that slightly decreased or normal ADAMTS13 activity and highly elevated VWF are rather biomarkers reflecting both the strong inflammation and the endothelial damage rather than drivers of the thrombotic process of COVID-19.
© 2021 International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  ADAMTS13; ADAMTS13 conformation; COVID-19; thrombotic microangiopathy; von Willebrand factor

Year:  2021        PMID: 34219357     DOI: 10.1111/jth.15445

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  8 in total

1.  Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19.

Authors:  Kristina Zguro; Margherita Baldassarri; Francesca Fava; Giada Beligni; Sergio Daga; Roberto Leoncini; Lucrezia Galasso; Michele Cirianni; Stefano Rusconi; Matteo Siano; Daniela Francisci; Elisabetta Schiaroli; Sauro Luchi; Giovanna Morelli; Enrico Martinelli; Massimo Girardis; Stefano Busani; Saverio Giuseppe Parisi; Sandro Panese; Carmelo Piscopo; Mario Capasso; Danilo Tacconi; Chiara Spertilli Raffaelli; Annarita Giliberti; Giulia Gori; Peter D Katsikis; Maria Lorubbio; Paola Calzoni; Agostino Ognibene; Monica Bocchia; Monica Tozzi; Alessandro Bucalossi; Giuseppe Marotta; Simone Furini; Alessandra Renieri; Chiara Fallerini
Journal:  Viruses       Date:  2022-05-29       Impact factor: 5.818

Review 2.  Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19.

Authors:  Denise Battaglini; Miquéias Lopes-Pacheco; Hugo C Castro-Faria-Neto; Paolo Pelosi; Patricia R M Rocco
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

Review 3.  COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm.

Authors:  Yoshihiro Fujimura; Linda Z Holland
Journal:  Int J Hematol       Date:  2022-03-22       Impact factor: 2.319

4.  Routine and Advanced Laboratory Tests for Hemostasis Disorders in COVID-19 Patients: A Prospective Cohort Study.

Authors:  Paul Billoir; Perrine Leprêtre; Caroline Thill; Jeremy Bellien; Veronique Le Cam Duchez; Jean Selim; Fabienne Tamion; Thomas Clavier; Emmanuel Besnier
Journal:  J Clin Med       Date:  2022-03-03       Impact factor: 4.241

5.  The Impact of Age and BMI on the VWF/ADAMTS13 Axis and Simultaneous Thrombin and Plasmin Generation in Hospitalized COVID-19 Patients.

Authors:  Kiruphagaran Thangaraju; Upendra Katneni; Imo J Akpan; Kenichi Tanaka; Tiffany Thomas; Saini Setua; Julie A Reisz; Francesca Cendali; Fabia Gamboni; Travis Nemkov; Stacie Kahn; Alexander Z Wei; Jacob E Valk; Krystalyn E Hudson; David J Roh; Chiara Moriconi; James C Zimring; Angelo D'Alessandro; Steven L Spitalnik; Richard O Francis; Paul W Buehler
Journal:  Front Med (Lausanne)       Date:  2022-01-10

Review 6.  Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.

Authors:  Xin Xu; Yao Feng; Yitong Jia; Xiao Zhang; Long Li; Xuesong Bai; Liqun Jiao
Journal:  Thromb Res       Date:  2022-08-18       Impact factor: 10.407

7.  Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.

Authors:  György Sinkovits; Marienn Réti; Veronika Müller; Zsolt Iványi; János Gál; László Gopcsa; Péter Reményi; Beáta Szathmáry; Botond Lakatos; János Szlávik; Ilona Bobek; Zita Z Prohászka; Zsolt Förhécz; Blanka Mező; Dorottya Csuka; Lisa Hurler; Erika Kajdácsi; László Cervenak; Petra Kiszel; Tamás Masszi; István Vályi-Nagy; Zoltán Prohászka
Journal:  Thromb Haemost       Date:  2022-01-21       Impact factor: 5.249

Review 8.  Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination.

Authors:  Shinya Yamada; Hidesaku Asakura
Journal:  Int J Mol Sci       Date:  2022-03-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.